Previous 10 | Next 10 |
THE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2020. “We achieved 21% growth in XERMELO net sales in the U.S. for the seco...
THE WOODLANDS, Texas, July 23, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a...
Biohaven completes enrollment in Phase 3 clinical trial for Multiple System Atrophy Biohaven Pharmaceutical Holding Company Ltd. ( BHVN ) reported that it successfully met its enrollment targets for the M-STAR study. The trial investigates Verdiperstat as a treatment for multiple system ...
Quick Take Nurix Therapeutics ( NRIX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing drug candidates to treat various cancers. NRIX has significant collaboration partners and a top ti...
Immuron (NASDAQ: IMRN ) +114% on potential of hyperimmune bovine antibodies in COVID-19. More news on: Immuron Limited, Midatech Pharma plc, New Age Beverages Corporation, , , Stocks on the move Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) announces positive results from four Phase 3 clinical trials, SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS, evaluating Zynquista (sotagliflozin) in patients with type 2 diabetes (T2D). All four met the primary endpoints of lowering A1C. More news o...
THE WOODLANDS, Texas, July 21, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The final results of these studies will be preserved...
THE WOODLANDS, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that four posters highlighting XERMELO ® (telotristat ethyl) will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference (July 22-24). P...
Quick Take Nurix Therapeutics ( NRIX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is developing small molecule-based treatments for blood cancers and immune system conditions. NRIX is a promising biopharma with...
THE WOODLANDS, Texas, June 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for Zynquista TM (sotagliflozin) at the virtual 80 th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safet...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...